marked.bio

Company

Guangzhou JOYO Pharma

4 active trials that select patients by a biomarker on marked.bio, across 1 biomarker; 2 in phase 3.

Counts only trials this company leads as sponsor, not partnered or academic trials of its drugs.

Biomarkers

Drugs in these trials

Targeted, immune and antibody-drug-conjugate therapies named in the company's active biomarker-selected trials (including other companies' drugs used in combination).

JYP0322 3crizotinib 1

Trials

4 of 4 trials shown

  1. A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    Not yet recruiting Phase 3 Guangzhou JOYO Pharma Started 2026Primary completion 2028-12 NCT07816380

    JYP0322crizotinib FDA EU

    …dition stage IIIB or IIIC not amenable to multimodality therapy) or metastatic (stage IV) ROS1-positive non-small cell lung cancer (NSCLC).

    ROS1 fusionNSCLC (Advanced Non-small Cell Lung Cancer)

  2. JYP0322 Versus Platinum Based Doublet Chemotherapy in ROS1 Positive Patients Previously Treated With ROS1-TKIs.

    Not yet recruiting Phase 3 Guangzhou JOYO Pharma Started 2025Primary completion 2027-10 NCT07154368

    pemetrexedJYP0322

    Locally advanced or metastatic ROS1 fusion positive NSCLC.

    ROS1 fusionNon Small Cell Lung Cancer

  3. Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

    Recruiting Phase 2 Guangzhou JOYO Pharma Started 2025Primary completion 2026-03 NCT06895031

    JYP0015

    Histologically or pathologically confirmed solid tumors with RAS mutation via molecular tests.

    KRAS G12CKRAS G12DSolid Tumor, Pancreatic Ductal Adenocarcinoma (PDAC), Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)

  4. Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors

    Recruiting Phase 1 Guangzhou JOYO Pharma Started 2022Primary completion 2026-06 NCT06128148

    JYP0322

    Phase I Study of JYP0322 in ROS1 Fusion-Positive Solid Tumors

    ROS1 fusionProtein Kinase Inhibitors, Other Protocol Specified Criteria, Lung Neoplasms, Brain Neoplasms